Our finding demonstrates that HDCA is a promising therapeutic agent for NAFLD and provides a therapeutic strategy for NAFLD by targeting the PPARα shuttling mechanism. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.